David Raben, M.D., is a renowned radiation oncologist and clinical researcher serving as Chief Medical Officer at Bicara Therapeutics Inc., a clinical-stage biotechnology company developing bifunctional tumor-targeting antibodies for solid tumors. With more than 25 years of experience in oncology, Dr. Raben has focused on advancing therapies for head and neck squamous cell carcinoma (HNSCC) and other challenging cancers. He earned his medical degree from the University of Vermont College of Medicine, completed residency training in radiation oncology at Johns Hopkins University, and pursued advanced fellowship training in head and neck oncology. Throughout his career, Dr. Raben has held leadership roles, including Professor of Radiation Oncology and Vice Chair of Research at the University of Colorado Anschutz Medical Campus, where he directed innovative clinical trials combining radiation with targeted agents like EGFR inhibitors and immunotherapies such as PD-1 inhibitors. His prolific research output includes over 150 peer-reviewed publications, numerous grants from the National Cancer Institute, and pivotal contributions to FDA approvals and guideline changes in HNSCC treatment. Recognized for bridging translational research and clinical practice, Dr. Raben has trained generations of oncologists and presented at major international conferences. In his role at Bicara Therapeutics, Dr. Raben leads the clinical development organization, overseeing Phase 1/2 trials of the company's lead asset, ficerafusp alfa (BCA101), an EGFRCam/EGFR-targeted IL-2 cytokine designed to enhance anti-tumor immunity while minimizing toxicity. His strategic vision drives the pipeline's advancement into late-stage development, positioning Bicara to deliver transformative therapies for patients with difficult-to-treat solid tumors.